

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(S1) International Patent Classification 6 : <b>A61K 31/445, 31/135</b>	A1	(11) International Publication Number: <b>WO 99/03469</b> (43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/GB98/02073		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 14 July 1998 (14.07.98)		
(30) Priority Data: 9714841.5 14 July 1997 (14.07.97) GB		
(71) Applicant ( <i>for all designated States except US</i> ): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		
(72) Inventor; and		Published
(75) Inventor/Applicant ( <i>for US only</i> ): JENNER, Paul, Norman [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).		With international search report.
(74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		
(54) Title: TREATMENT AND PREVENTION OF CARDIAC DISORDERS USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRI)		
(57) Abstract		
A method for treating and/or preventing cardiac disorders in human or non-human animals comprises administering an effective, non-toxic amount of an SSRI or a pharmaceutically acceptable salt thereof, to a human or non-human animal in need thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republie of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## TREATMENT AND PREVENTION OF CARDIAC DISORDERS USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRI)

The present invention relates to a method for the treatment and/or prevention of cardiac disorders associated with the pathogenesis of thrombosis such as myocardial infarction, using an SSRI such as paroxetine.

Selective serotonin re-uptake inhibitors (SSRI's) are a class of compounds which are well known in the field of treating/preventing depression.

In particularly, U.S. Patent 4 007 196 discloses the compound, (-)-*trans*-4-(4'-fluorophenyl)-3-(3'4'-methylenedioxy-phenoxyethyl)piperidine, and, in Example 2, a process by which it can be prepared. The compound, which is referred to herein by its common name, paroxetine, is described in the patent as an inhibitor of 5-hydroxytryptamine uptake and, therefore, is of use in the treatment of depression.

Other SSRI include fluoxetine, sertraline, citalopram and fluvoxamine.

It has now been discovered that SSRI's such as paroxetine, fluvoxamine, sertraline and citalopram also have potential therapeutic utility for treating and/or preventing cardiac disorders such as disorders associated with the pathogenesis of thrombosis such as myocardial infarction.

Accordingly, the present invention provides a method for treating and/or preventing cardiac disorders such as disorders associate with the pathogenesis of thrombosis such as myocardial infarction in human or non-human animals, which method comprises administering an effective, non-toxic amount of an SSRI or a pharmaceutically acceptable salt thereof, to human or non-human animals in need thereof.

The present invention also provides the use of an SSRI or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of and/or prevention of cardiac disorders such as discorders associated with the pathogenesis of thrombosis such as myocardial infarction.

Preferred SSRI's include paroxetine, fluoxetine, citalopram and fluvoxamine.

Examples of pharmaceutically acceptable salts of SSRI's such as fluvoxamine, citalopram sertraline and fluvoxamine are hydrochloride, hydrobromide, acetate and maleate, A preferred salt of paroxetine is the crystalline hydrochloride hemi-hydrate.

An SSRI medicament, for use in the treatment and/or prevention of cardiac disorders such as disorders associated with the pathogenesis of thrombosis such as myocardial infarction may be prepared by admixture of an SSRI or salt thereof with an appropriate carrier, which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.

Preferably, the medicament is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form

accompanied by written or printed instructions for use as an agent in the treatment and/or prevention of cardiac disorders such as myocardial infarction.

The suitable dosage range for an SSRI or a salt depends on the severity of the cardiac disorders such as disorders associated with the pathogenesis of thrombosis such as 5 myocardial infarction and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.

An SSRI or a salt thereof may be formulated for administration by any route, and examples are oral, rectal, topical, parenteral, intravenous or intramuscular administration.

10 Preparations may, if desired, be designed to give slow release of the SSRI.

The medicaments may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.

15 The medicaments, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycerine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting 20 agents such as sodium lauryl sulphate.

Solid medicaments may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute paroxetine or a salt thereof throughout those medicaments employing large quantities of fillers.

When the medicament is in the form of a tablet, powder, or lozenge, any carrier suitable 25 for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The medicament may also be in the form of an ingestible capsule, for example of gelatin containing paroxetine or a salt thereof if desired with a carrier or 30 other excipients.

Medicaments for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid medicaments may contain conventional additives such as suspending agents, for example sorbitol, 35 syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible

§

oils, for example almond oil, fractionated coconut oil, oily esters, for example water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

An SSRI or salt thereof may also be administered by a non-oral route. In  
5 accordance with routine pharmaceutical procedure, the medicaments may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to  
10 render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi-dose forms such as bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.

15 As mentioned hereinabove, the effective dose of the SSRI depends on the severity of the cardiac disorders such as disorders associated with the pathogenesis such as myocardial infarction, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 2 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 20, 50, 100, 150, 200, 250, 300, 350, 400, 450,  
20 or 500 mg. The composition may be administered once or more times daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. In the case of paroxetine the unit dose will contain from 2 to 20 mg of paroxetine and be administered in multiples, if desired, to give the preceding daily dose.

The present invention further provides a pharmaceutical composition for use in  
25 the treatment and/or prevention of cardiac disorders such as disorders associated with the pathogenesis of thrombosis such as myocardial infarction which comprises an effective amount of an SSRI or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Such compositions may be prepared in the manner as hereinbefore described.

30 The following example demonstrates a suitable pharmaceutical composition:

Example 1

The following were mixed together in a conventional manner and compressed into a tablet in a conventional manner.

35 22.88 mg Paroxetine hydrochloride hemihydrate  
244.12 mg Dibasic calcium phosphate dihydrate  
15.00 mg Hydroxypropylmethyl cellulose 2910

15.00 mg Sodium starch glycollate  
3.00 mg Magnesium Stearate  
300.00 mg Total tablet weight

5 Clinical Data

The medical records of 3374 patients who were prescribed on SSRI between February 1989 and January 1993 were examined.

The rate of myocardial infarction for these patients was found to be 0.0204 events per patient year exposure whilst the rate for the general population not taking an SSRI 10 was 0.0226 which demonstrates that patients taking SSRI are statistically less likely to develop a myocardial infarction than those who do not.

**Claims**

1. A method for treating and/or preventing cardiac disorders in human or non-human animals, which method comprises administering an effective, non-toxic amount of an SSRI or a pharmaceutically acceptable salt thereof, to a human or non-human animal in need thereof.
2. Use of an SSRI or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of and/or prevention of cardiac disorders.
3. A method according to claim 1 or use according to claim 2 wherein the SSRI is selected from the group consisting of paroxetine, fluoxetine, citalopram and fluvoxamine.
4. A pharmaceutical composition for use in the treatment and/or prevention of cardiac disorders which comprises an effective amount of an SSRI or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

# INTERNATIONAL SEARCH REPORT

Inte onal Application No  
PCT/GB 98/02073

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/445 A61K31/135

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CARNEY R.M., ET AL.: "Depression and coronary heart disease: A review for cardiologists" CLINICAL CARDIOLOGY, vol. 20, no. 3, March 1997, pages 196-200, XP002082023 *cf. p. 196, summary and introduction, page 198, right col., last para. with page 199, left col., first para., also same page, right col., table II* ---	1-4
X	EP 0 768 083 A (PFIZER) 16 April 1997 *cf. abstract, p. 3, lines 35-44* ---	1-4 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 October 1998

Date of mailing of the International search report

12/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040; Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02073

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>TIKAL K., ET AL.: "Indications for antidepressive agents in relation to diseases of the cardiovascular system"            PSYCHIATRICKA LECEBNA KOSMONOSY.            CESKOSLOVENSKA PSYCHIATRIE,            vol. 89, no. 3, June 1993, pages 163-165,            XP002082024            *cf. summary in english language*</p> <p>---</p>	1-4
Y	<p>GLASSMAN A. H., ET AL.: "Review of the cardiovascular effects of heterocyclic antidepressants"            J. CLIN. PSYCHIATRY,            vol. 54, no. 2, February 1993, pages            16-22, XP002082025            *cf. abstract and page 20, right col.,            last para..*</p> <p>-----</p>	1-4

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02073

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0768083	A 16-04-1997	AU 6053496	A	23-01-1997
		CA 2181225	A	18-01-1997
		CN 1147937	A	23-04-1997
		JP 9030959	A	04-02-1997